A Novel Dual PI3K/mTOR Inhibitor, XIN-10, for the Treatment of Cancer
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241914821 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Leixuan Luo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, 605 Fenglin Road…. Hauptthemen laut MEDLINE: Breast Neoplasms, MTOR Inhibitors, Phosphatidylinositol 3-Kinases, Phosphoinositide-3 Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangxi, China, Jiangxi Science and Technology Normal University Young Top Talent Support Program.
Abstract (Originalsprache)
An imbalance in PI3K/AKT/mTOR pathway signaling in humans often leads to cancer. Therefore, the investigation of anti-cancer medications that inhibit PI3K and mTOR has emerged as a significant area of research. The aim of this study was to explore the effect of XIN-10, a dual PI3K/mTOR inhibitor, on the growth as well as antiproliferation of tumor cells and to investigate the anti-tumor mechanism of XIN-10 by further exploration. We screened three cell lines for more in-depth exploration by MTT experiments. From the AO staining, cell cycle and apoptosis, we found that XIN-10 had a more obvious inhibitory effect on the MCF-7 breast cancer cell line and used this as a selection for more in-depth experiments. A series of in vitro and in vivo experiments showed that XIN-10 has superior antiproliferative activity compared with the positive drug GDC-0941. Meanwhile, through the results of protein blotting and PCR experiments, we concluded that XIN-10 can block the activation of the downstream pathway of mTOR by inhibiting the phosphorylation of AKT(S473) as well as having significant inhibitory effects on the gene exons of PI3K and mTOR. These results indicate that XIN-10 is a highly potent inhibitor with low toxicity and has a strong potential to be developed as a novel PI3Kα/mTOR dual inhibitor candidate for the treatment of positive breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, 605 Fenglin Road, Nanchang 330013, China.
ORCID-Profile: Wufu Zhu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangxi, China
- Jiangxi Science and Technology Normal University Young Top Talent Support Program
- Science and Technology Project Founded by the Education Department of Jiangxi Province, China
Zitieren
APA
Luo, L., Sun, X., Yang, Y., Xia, L., Wang, S., Fu, Y., Zhu, Y., Xu, S., & Zhu, W. (2023). A Novel Dual PI3K/mTOR Inhibitor, XIN-10, for the Treatment of Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241914821
Vancouver
Luo L, Sun X, Yang Y, Xia L, Wang S, Fu Y, et al. A Novel Dual PI3K/mTOR Inhibitor, XIN-10, for the Treatment of Cancer. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241914821
BibTeX
@article{Luo2023,
author = {Luo, Leixuan and Sun, Xin and Yang, Yang and Xia, Lulu and Wang, Shiyu and Fu, Yuxing and Zhu, Yuxuan and Xu, Shan and Zhu, Wufu},
title = {A Novel Dual PI3K/mTOR Inhibitor, XIN-10, for the Treatment of Cancer},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241914821}
}
EUVIMED